PANK1 and pantothenate kinase-associated neurodegeneration: In a recently published randomized controlled trial in patients with pantothenate kinase-associated neurodegeneration (PKAN), the most common form of NBIA, deferiprone seemed to have more potential to slow disease progression when it was initiated in patients with less advanced stages of neurodegeneration [50].